Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Extension Study of LdT (Telbivudine), Lamivudine or LdT Plus Lamivudine in Patients With Chronic Hepatitis B Who Have Completed Study NV-02B-003

NCT00124241 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00124241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00124241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Extension Study of LdT (Telbivudine), Lamivudine or LdT Plus Lamivudine in Patients With Chronic Hepatitis B Who Have Completed Study NV-02B-003
Lead sponsor
Novartis
Phase
Phase 2
Overall status
Completed
Start date
Not reported
Completion date
November 30, 2005
Enrollment
Not reported
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b